• 1
    Horn J. The proton-pump inhibitors: similarities and differences. Clin Ther 2000; 22: 26680.
  • 2
    Williams MP, Usselmann B, Chilton A, Sercombe J, Nwokolo CU, Pounder RE. Eradication of Helicobacter pylori increases nocturnal intragastric acidity during dosing with rabeprazole, omeprazole, lansoprazole and placebo. Aliment Pharmacol Ther 2003; 17: 77583.
  • 3
    Calam J. Helicobacter pylori modulation of gastric acid. Yale J Biol Med 1999; 72: 195202.
  • 4
    Furuta T, Baba S, Takashima M, et al. H+/K+-adenosine triphosphatase mRNA in gastric fundic gland mucosa in patients infected with Helicobacter pylori. Scand J Gastroenterol 1999; 34: 38490.
  • 5
    Meining A, Wick M, Miehlke S, et al. The presence of immunoglobulins in the gastric juice of patients infected with Helicobacter pylori is related to a reduced secretion of acid. Helicobacter 2002; 7: 6770.
  • 6
    Attar M, Lee VH. Pharmacogenomic considerations in drug delivery. Pharmacogenomics 2003; 4: 44361.
  • 7
    Chong E, Ensom MH. Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy 2003; 23: 46071.
  • 8
    Yacyshyn BR, Thomson AB. The clinical importance of proton pump inhibitor pharmacokinetics. Digestion 2002; 66: 6778.
  • 9
    Landes BD, Petite JP, Flouvat B. Clinical pharmacokinetics of lansoprazole. Clin Pharmacokinet 1995; 28: 45870.
  • 10
    Andersson T, Hassan-Alin M, Hasselgren G, Röhss K, Weidolf L. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 2001; 40: 41126.
  • 11
    Humphries TJ, Merritt GJ. Review article: drug interactions with agents used to treat acid-related diseases. Aliment Pharmacol Ther 1999; 13(Suppl. 3): 1826.
  • 12
    Fuhr U, Jetter A. Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions. Pharmazie 2002; 57: 595601.
  • 13
    Robinson M. New-generation proton pump inhibitors: overcoming the limitations of early-generation agents. Eur J Gastroenterol Hepatol 2001; 13(Suppl. 1): S437.
  • 14
    Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001; 52: 34955.
  • 15
    Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41: 91358.
  • 16
    Sakai T, Aoyama N, Kita T, et al. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm Res 2001; 18: 7217.
  • 17
    Yasuda S, Horai Y, Tomono Y, et al. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status. Clin Pharmacol Ther 1995; 58: 14354.
  • 18
    Horai Y, Kimura M, Furuie H, et al. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. Aliment Pharmacol Ther 2001; 15: 793803.
  • 19
    Kita T, Sakaeda T, Baba T, et al. Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors. Biol Pharm Bull 2003; 26: 38690.
  • 20
    Lin CJ, Yang JC, Uang YS, Chern HD, Wang TH. Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers. Pharmacotherapy 2003; 23: 7119.
  • 21
    Hatlebakk JG, Berstad A. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease. Clin Pharmacokinet 1996; 31: 386406.
  • 22
    Saitoh T, Fukushima Y, Otsuka H, et al. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment Pharmacol Ther 2002; 16: 18117.
  • 23
    Shirai N, Furuta T, Moriyama Y, et al. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 2001; 15: 192937.
  • 24
    Adachi K, Katsube T, Kawamura A, et al. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment Pharmacol Ther 2000; 14: 125966.
  • 25
    Wang H, Nie YQ, Dai SJ, She QZ, Li YY. [The effect of proton pump inhibitor on intragastric acidity and it relation to S-mephenytoin hydroxylase genetic polymorphism] (in Chinese). Zhonghua Nei Ke Za Zhi 2003; 42: 77780.
  • 26
    Erah PO, Goddard AF, Barrett DA, Shaw PN, Spiller RC. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother 1997; 39: 512.
  • 27
    Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J Biol Chem 1997; 272: 2243846.
  • 28
    Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther 2003; 17: 150714.
  • 29
    Inamori M, Togawa J, Takahashi K, et al. Comparison of the effect on intragastric pH of a single dose of omeprazole or rabeprazole: which is suitable for on-demand therapy?J Gastroenterol Hepatol 2003; 18: 10348.
  • 30
    He XX, Zhao YH, Hao YT. [Effect of CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with rabeprazole-based triple therapy] (in Chinese). Zhonghua Nei Ke Za Zhi 2004; 43: 135.
  • 31
    Hokari K, Sugiyama T, Kato M, et al. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism. Aliment Pharmacol Ther 2001; 15: 147984.
  • 32
    Lee SB, Park SJ, Ryu JK, et al. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype. Korean J Gastroenterol 2003; 42: 46875.
  • 33
    Isomoto H, Inoue K, Furusu H, et al. High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection. Aliment Pharmacol Ther 2003; 18: 1017.
  • 34
    Kawabata H, Habu Y, Tomioka H, et al. Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. Aliment Pharmacol Ther 2003; 17: 25964.
  • 35
    Kawamura M, Ohara S, Koike T, et al. The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism. Aliment Pharmacol Ther 2003; 17: 96573.
  • 36
    Furuta T, Shirai N, Watanabe F, et al. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther 2002; 72: 45360.
  • 37
    Dresser GK, Bailey DG. A basic conceptual and practical overview of interactions with highly prescribed drugs. Can J Clin Pharmacol 2002; 9: 1918.
  • 38
    McCarthy DM, McLaughlin TP, Griffis DL, Yazdani C. Impact of cotherapy with some proton pump inhibitors on medical claims among HMO patients already using other common drugs also cleared by cytochrome P450. Am J Ther 2003; 10: 33040.
  • 39
    Gerson LB, Triadafilopoulos G. Proton pump inhibitors and their drug interactions: an evidence-based approach. Eur J Gastroenterol Hepatol 2001; 13: 6116.
  • 40
    Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors – emphasis on rabeprazole. Aliment Pharmacol Ther 1999; 13(Suppl. 3): 2736.